4.1 Physicochemical Properties of Drugs

4.1 Physicochemical Properties of Drugs

Core Concept: The absorption, distribution, metabolism, and excretion (ADME) of a therapeutic agent are fundamentally governed by its physicochemical properties. Key parameters including acid dissociation constant ($p K_a$), environmental $p H$, lipophilicity ($\log P$), and aqueous solubility dictate how a drug molecule interacts with biological membranes and formulation matrices.

Understanding these molecular characteristics allows pharmaceutical scientists to predict systemic absorption across mucosal barriers, optimize drug stability, and select appropriate formulation technologies for poorly soluble compounds.

---

1. Drug Ionization, pH, and pKa

Most active pharmaceutical ingredients (APIs) are weak organic acids or weak organic bases. Unlike strong acids or bases that completely dissociate in aqueous solution, weak electrolytes exist in a dynamic equilibrium between their un-ionized (uncharged, molecular) and ionized (charged, ionic) forms.

The acid dissociation constant ($K_a$), expressed logarithmically as $p K_a = -\log_{10}(K_a)$, is the specific $p H$ at which a drug molecule exists in exact $50:50$ equilibrium between its ionized and un-ionized states. The relative proportion of ionized to un-ionized species at any physiological $p H$ is quantitatively expressed by the Henderson-Hasselbalch equation.

Mathematical Equations

For a weak acid ($HA \rightleftharpoons H^+ + A^-$):

$p H = p K_a + \log_{10}\left( \frac{[A^-]}{[HA]} \right) = p K_a + \log_{10}\left( \frac{[\text{Ionized}]}{[\text{Un-ionized}]} \right)$

Rearranging to determine the percentage of ionized weak acid:

$\% \text{ Ionized (Weak Acid)} = \frac{100}{1 + 10^{(p K_a - p H)}}$

For a weak base ($BH^+ \rightleftharpoons H^+ + B$):

$p H = p K_a + \log_{10}\left( \frac{[B]}{[BH^+]} \right) = p K_a + \log_{10}\left( \frac{[\text{Un-ionized}]}{[\text{Ionized}]} \right)$

Rearranging to determine the percentage of ionized weak base:

$\% \text{ Ionized (Weak Base)} = \frac{100}{1 + 10^{(p H - p K_a)}}$

Clinical and Pharmacokinetic Implications

• When environmental $p H < p K_a$, acidic environment forces weak acids into their un-ionized form ($HA$), while weak bases become predominantly ionized ($BH^+$).
• When environmental $p H > p K_a$, alkaline environment forces weak acids into their ionized form ($A^-$), while weak bases become predominantly un-ionized ($B$).
• Rule of Thumb: A $p H$ shift of $1$ unit away from $p K_a$ changes the ratio of ionized to un-ionized drug by a factor of $10$; a shift of $2$ units changes the ratio by a factor of $100$.

---

2. Ionization State vs. Lipid Solubility & Passive Membrane Diffusion

Biological membranes consist of a hydrophobic phospholipid bilayer embedded with proteins. According to the pH-Partition Hypothesis, only un-ionized, non-polar drug molecules possess sufficient lipophilicity to partition into and passively diffuse across lipid membranes.

[Gastric Lumen: pH 1.5]            [Lipid Membrane]           [Blood Plasma: pH 7.4]
Weak Acid (HA) [Un-ionized]   <--->  Passive Diffusion  <--->  Weak Acid (HA) [Un-ionized]
   ^
   v                                                                  v
Ionized (A-) [Low Conc.]                                        Ionized (A-) [High Conc.] (Trapped)

Ion Trapping Mechanism

When a total concentration gradient exists across membranes with a $p H$ differential (e.g., stomach $p H \approx 1.5$ vs. plasma $p H \approx 7.4$), un-ionized drug equilibrates rapidly across the membrane. However, once in the higher $p H$ plasma, weak acids ($p K_a \approx 3.5$, e.g., aspirin) dissociate into ionized species ($A^-$). Because $A^-$ cannot cross back across the lipid barrier, the drug accumulates in plasma—a phenomenon known as ion trapping.

Conversely, clinical toxicologists exploit ion trapping during drug overdose management. Alkalinizing the urine with intravenous sodium bicarbonate ($p H > 7.5$) converts weak acids (such as phenobarbital or salicylates) into their ionized state within renal tubules, preventing tubular reabsorption and accelerating urinary excretion.

Fick's First Law of Diffusion

Passive membrane transport driven by a concentration gradient is quantitatively defined by Fick's First Law:

$J = \frac{D \cdot K \cdot A \cdot (C_1 - C_2)}{h}$

---

3. Partition Coefficient (log P & log D)

The partition coefficient ($P$ or $K_{o/w}$) measures a drug's relative lipophilicity by calculating its equilibrium concentration ratio between an organic phase ($n$-octanol) and an aqueous phase (water):

$P = \frac{[C_{\text{octanol}}]}{[C_{\text{water}}]_{\text{un-ionized}}}$

Because partition coefficients span multiple orders of magnitude, values are expressed logarithmically as $\log P$.

• $\log P > 0$: Hydrophobic/lipophilic molecule (prefers octanol).
• $\log P < 0$: Hydrophilic/polar molecule (prefers water).
• Optimal Range: Most orally bioavailable drugs possess a $\log P$ between $1$ and $3$. Drugs with $\log P > 5$ suffer from poor aqueous solubility and erratic dissolution, while drugs with $\log P < 0$ exhibit poor membrane permeability.

Distribution Coefficient ($\log D$)

While $\log P$ measures only the un-ionized species, the distribution coefficient ($\log D$) measures the combined equilibrium distribution of both ionized and un-ionized forms at a specific physiological $p H$:

$\log D_{\text{acid}} = \log P - \log_{10}\left(1 + 10^{(p H - p K_a)}\right)$

$\log D_{\text{base}} = \log P - \log_{10}\left(1 + 10^{(p K_a - p H)}\right)$

$\log D$ provides a far more accurate biological prediction of tissue distribution and membrane permeability in different anatomical compartments.

---

4. Drug Solubility Enhancement Techniques

Under the Biopharmaceutics Classification System (BCS), drugs are categorized into four classes based on aqueous solubility and intestinal permeability:

Over $40\%$ of newly discovered small molecules fall into BCS Class II. To overcome poor aqueous solubility, formulation scientists utilize several established chemical and physical enhancement strategies:

1. Salt Formation: Converting a weak acid/base into a crystalline salt (e.g., naproxen sodium, diltiazem $HCl$) alters the micro-environmental $p H$ ($p H_{\text{max}}$) surrounding the dissolving particle, significantly accelerating dissolution rate according to the Noyes-Whitney equation.
2. Particle Size Reduction (Micronization and Nanonization): Reducing particle size from micrometers to nanometers dramatically increases effective specific surface area ($A$), elevating dissolution velocity.
3. Amorphous Solid Dispersions (ASDs): Dispersing an active drug within a hydrophilic polymeric matrix (such as HPMC or PVP) disrupts the crystal lattice. Because amorphous forms lack lattice energy barriers, they generate supersaturated solutions upon contact with gastrointestinal fluid.
4. Cyclodextrin Complexation: Cyclic oligosaccharides ($\alpha$-, $\beta$-, $\gamma$-cyclodextrins and hydroxypropyl-$\beta$-cyclodextrin) possess a hydrophobic central cavity and a hydrophilic exterior. Lipophilic drugs entrap within the cavity via non-covalent inclusion complexes, enhancing apparent aqueous solubility.
5. Self-Emulsifying Drug Delivery Systems (SEDDS/SMEDDS): Isotropic mixtures of oils, surfactants, and co-solvents that spontaneously form fine oil-in-water nano-emulsions ($\le 100 \text{ nm}$) upon mild agitation in GI fluids, presenting the lipophilic drug in pre-dissolved droplets for rapid absorption.